Related Experiment Video
Updated: Aug 5, 2026
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Resveratrol Nanoformulations for Cancer Management: A Comprehensive Review of Disease-Specific Strategies and
Huifang Yang1, Zilin Cheng1, Yilin Wang1
1Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
Abstract:
Cancer remains a leading cause of mortality worldwide, highlighting the need for therapeutic strategies that reduce systemic toxicity and drug resistance. Resveratrol (RES), a natural polyphenolic stilbenoid, possesses antioxidant, anti-inflammatory, pro-apoptotic, anti-metastatic, and chemosensitizing activities. However, its clinical translation is limited by poor aqueous solubility, chemical instability, rapid metabolic clearance, and consequently low systemic bioavailability. Nanotechnology-based drug delivery systems provide a promising strategy to address these limitations. This review summarizes recent advances in RES-loaded nanoformulations, including polymeric nanoparticles, liposomes, solid lipid nanoparticles, micelles, inorganic nanocarriers, protein-based systems, and biomimetic vesicles. Their therapeutic performance is evaluated across prostate, lung, colorectal, breast, and other cancers, with attention to tumor targeting, controlled release, combination therapy, multidrug-resistance reversal, and modulation of cancer-relevant pathways such as NF-κB, p53, and PI3K/Akt/mTOR. Current oncology-related clinical evidence for RES is still largely based on conventional oral or micronized formulations. Translation of engineered RES nanocarriers therefore requires stronger evidence on scalable manufacturing, carrier-specific safety, heterogeneous tumor delivery, and biomarker-guided trial design. This review also introduces a semi-quantitative prioritization framework based on model-readiness, translational priority, and safety-alert scoring for future PBPK, PK-PD, nano-QSAR, and machine-learning analyses.
Insights
Resveratrol (RES) nanoformulations show promise for cancer therapy by overcoming poor bioavailability. Further research is needed for clinical translation of these advanced drug delivery systems.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Cancer is a leading cause of death globally, necessitating novel therapies with reduced toxicity and drug resistance.
- Resveratrol (RES), a natural compound, exhibits anticancer properties but suffers from poor bioavailability, limiting its clinical use.
- Nanotechnology offers a solution to enhance RES delivery and efficacy.
Purpose of the Study:
- To review recent advancements in Resveratrol (RES)-loaded nanoformulations for cancer treatment.
- To evaluate the therapeutic performance of various RES nanoformulations in different cancer types.
- To identify challenges and propose a framework for the clinical translation of RES nanocarriers.
Main Methods:
- Comprehensive literature review of RES nanoformulations.
- Analysis of therapeutic outcomes in preclinical cancer models (prostate, lung, colorectal, breast, etc.).
- Evaluation of tumor targeting, controlled release, and resistance reversal strategies.
- Assessment of modulation of key cancer pathways (NF-κB, p53, PI3K/Akt/mTOR).
Main Results:
- Various RES nanoformulations (nanoparticles, liposomes, micelles, etc.) demonstrate improved anticancer effects.
- These systems enhance tumor targeting, controlled drug release, and overcome multidrug resistance.
- RES nanoformulations modulate critical cancer-related signaling pathways.
Conclusions:
- RES nanoformulations represent a promising strategy to improve cancer therapy efficacy and overcome RES limitations.
- Scalable manufacturing, safety, targeted delivery, and biomarker-guided trials are crucial for clinical translation.
- A prioritization framework is proposed for future translational studies and computational analyses.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:59Cancer Prevention
Some...